Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

被引：0
|
作者：
Mezquita, L. [1 ]
Remon, J. [1 ]
Nicotra, C. [2 ]
Noerholm, M. [3 ]
Brinkmann, K. [3 ]
Planchard, D. [4 ]
Jovelet, C. [5 ]
Auclin, E. [6 ]
Flinspach, C. [3 ]
Hurley, J. [3 ]
Skog, J. [7 ]
Gazzah, A. [2 ]
Caramella, C. [8 ]
Adam, J. [9 ]
Lacroix, L. [5 ]
Auger, N. [9 ]
Friboulet, L. [10 ]
Soria, J. [11 ,12 ]
Besse, B. [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Gustave Roussy, Drug Dev Dept, Villejuif, France
[3] Exosome Diagnost GmbH, Martinsried, Germany
[4] Gustave Roussy, Med Oncol, Villejuif, France
[5] Gustave Roussy, Translat Res Lab, Villejuif, France
[6] Hop Georges Pompidou, Paris, France
[7] Exosome Diagnost Inc, Waltham, MA USA
[8] Gustave Roussy, Radiol Dept, Villejuif, France
[9] Gustave Roussy Canc Campus, Dept Med Biol & Pathol, Villejuif, France
[10] Gustave Roussy, Inserm U981 Lab, Villejuif, France
[11] Gustave Roussy Canc Campus, Drug Dev Dept, Paris, France
[12] Gustave Roussy Canc Campus, Inserm U981 Lab, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.03-013
引用
收藏
页码：S1954 / S1955
页数：2
相关论文
共 50 条
  • [1] Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Shaw, Alice T.
    Martini, Jean-Francois
    Besse, Benjamin
    Bauer, Todd M.
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Clancy, Jill S.
    Li, Sherry
    Thurm, Holger
    Satouchi, Miyako
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Solomon, Benjamin J.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
    Parisi, C.
    Benitez, J. C.
    Lecourt, H.
    Dall'Olio, F. G.
    Aldea, M.
    Blanc-Durand, F.
    Verge, V.
    Quivoron, C.
    Naltet, C.
    Abdayem, P.
    Lavaud, P.
    Ghigna, M. R.
    Loriot, Y.
    De Botton, S.
    Planchard, D.
    Barlesi, F.
    Soria, J-C.
    Ribrag, V.
    Friboulet, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S956 - S957
  • [3] Pathological features of ALK mutations in Malaysian non-small cell lung cancer (NSCLC) patients
    Ariffin, R. B.
    Daud, K. A. B.
    Muttalif, A. R. B. Abdul
    Marzuki, N. B. Mohd
    ANNALS OF ONCOLOGY, 2015, 26 : 10 - 10
  • [4] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [5] Therapeutic strategies in advanced ALK positive non-small cell lung cancer
    Tiotiu, A.
    Billon, Y.
    Vaillant, P.
    Menard, O.
    Hofman, P.
    Mascaux, C.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (10) : 1107 - 1116
  • [6] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [7] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [8] Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
    Kang, Jin
    Zhang, Xu-Chao
    Chen, Hua-Jun
    Zhong, Wen-Zhao
    Xu, Yang
    Su, Jian
    Zhou, Qing
    Tu, Hai-Yan
    Wang, Zhen
    Xu, Chong-Rui
    Yang, Xue-Ning
    Chen, Zhi-Hong
    Wu, Xue
    Zhang, Xian
    Shao, Yang
    Wu, Yi-Long
    Yang, Jin-Ji
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Schnell, Patrick
    Safferman, Allan Zachary
    Bartlett, Cynthia Huang
    Tang, Yiyun
    Wilner, Keith D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.
    Bearz, Alessandra
    Martini, Jean-Francois
    Jassem, Jacek
    Kim, Sang-We
    Chang, Gee-Chen
    Shaw, Alice
    Shepard, Deborah
    Dall'O', Elisa
    Polli, Anna
    Thurm, Holger
    Zalcman, Gerard
    Garcia Campelo, Maria Rosario
    Penkov, Konstantin
    Hayashi, Hidetoshi
    Solomon, Benjamin J.
    CANCER RESEARCH, 2021, 81 (13)
12345